Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Bayer
Boehringer Ingelheim
Compass Therapeutics
Compass Therapeutics
Novartis
Genentech, Inc.
Bristol-Myers Squibb
Travera Inc
OncoC4, Inc.
Genmab
USWM, LLC (dba US WorldMeds)
KaliVir Immunotherapeutics
Pfizer
Pfizer
Aulos Bioscience, Inc.
Ipsen
AstraZeneca
Sotio Biotech Inc.
Pfizer
Pfizer
Pfizer
Dragonfly Therapeutics
AstraZeneca
Seagen Inc.
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Endeavor Biomedicines, Inc.
Neonc Technologies, Inc.
ViroMissile, Inc.
Erasca, Inc.
Pfizer
Radiopharm Theranostics, Ltd
Arvinas Inc.
Tizona Therapeutics, Inc
Daiichi Sankyo
MacroGenics
DualityBio Inc.
MacroGenics
Adaptimmune
xCures
Daiichi Sankyo
Novartis
Natera, Inc.
Second Life Therapeutics
ImmunityBio, Inc.
Onchilles Pharma Inc
AbbVie
AgonOx, Inc.
Elephas